Commentary on cost-effectiveness of IV vs oral iron Authors: Callie Berkowitz, Joshua Rivenbark Published: 2026 TO THE EDITOR: By modeling societal costs and expected gains in quality-adjusted life years, authors Wang et al1 conclude in their recently published study that intravenous iron is cost-effective in comparison to oral iron for treatment of iron deficiency anemia (IDA) in women with heavy menstrual bleeding (HMB). A more complete incorporation of menstrual control and oral iron optimization strategies could impact findings. In the base case analysis, HMB is assumed to continue for 34 years. In a sensitivity analysis with HMB treatment, HMB is assumed to continue for 5 years before a 50% reduction in menstrual flow is observed. The reason for treatment delay is unclear. Is intravenous iron still more cost-effective if menstrual treatment is prompt and the most effective therapies (eg, levonorgestrel intrauterine devices, which reduce menstrual flow by >80%-90% within 6 months2) are used? In all models, oral iron is given for 6 months despite ongoing heavy menstruation and resumed when the accumulated deficit reaches 1 gram. Rather than awaiting recurrent IDA, several HMB clinical guidelines advise ongoing iron monitoring and supplementation.3,4 Proactive oral iron therapy (concurrent with HMB treatment) may prevent recurrence of IDA at a low cost and could tilt cost-effectiveness in favor of oral iron. More holistically, the quality-of-life (QoL) impact of treating anemia cannot be fully disentangled from its underlying cause of HMB. Both anemic and nonanemic women with HMB have similar QoL at baseline.5 In the Global Burden of Disease study6 (from which QoL improvements are modeled), the disability weights for IDA and anemia due to HMB are both derived from the same general anemia health states. If the burden of HMB itself, rather than solely the resultant IDA, is a strong QoL driver, the models may overestimate the benefits (and therefore cost-effectiveness) of iron supplementation when it is administered without any menstrual control measures. Conflict-of-interest disclosure: C.B. has received research funding from National Bleeding Disorder Foundation – Takeda and J.R. has received research funding from Agios Pharmaceuticals.